Phase 2 Study Of AG-013736 As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer.
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2015
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 24 Sep 2015 Results of effects of different degrees of renal impairment from one phase 3 and three phase 2 studies published in the Targeted Oncology.
- 15 Nov 2012 Planned End Date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.